Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2022 - 05 - 09 tags : Trial save search
Worldwide Clinical Trials Industry to 2031 - Featuring Novo Nordisk, PAREXEL International and Pfizer Among Others
Published: 2022-05-09 (Crawled : 20:00) - prnewswire.com
IQV | $227.25 -0.83% -0.15% 1.2K
|
Health Services
|
| O: 1.45%
H: 0.79%
C: -1.85%
LLY | News | $750.77 0.54% 0.15% 8.3K
|
Health Technology
|
| O: 0.93%
H: 0.0%
C: 0.0%
SNY | News | $46.11 0.68% 0.7% 66K
|
Health Technology
|
| O: 1.06%
H: 0.0%
C: 0.0%
ICLR | $292.02 -0.68% -0.75% 1
|
Health Technology
|
| O: 1.16%
H: 1.61%
C: -0.74%
trials international trial
MoonLake Immunotherapeutics announces the publication of new long-term disease control data from a Phase 2b Psoriasis trial of the Nanobody® sonelokimab
Published: 2022-05-09 (Crawled : 14:00) - biospace.com/
SNY | News | $46.11 0.68% 0.7% 66K
|
Health Technology
|
| O: -0.84%
H: 0.0%
C: 0.0%
nanobody disease control trial psoriasis publication phase 2b
Achilles Therapeutics Doses First Patient with Higher-dose cNeT in Phase I/IIa CHIRON Trial in Advanced NSCLC and Initiates Enrollment in Cohort B of the THETIS Trial (cNeT + PD-1 checkpoint inhibitor) in Metastatic Malignant Melanoma
Published: 2022-05-09 (Crawled : 14:00) - biospace.com/
ACHL | $0.8145 1.53% -0.28% 100
|
Manufacturing
|
| O: 0.46%
H: 1.84%
C: -9.68%
trial therapeutics enroll
LogicBio Therapeutics Announces FDA Lifts Clinical Hold on SUNRISE Trial in Pediatric Patients with Methylmalonic Acidemia
Published: 2022-05-09 (Crawled : 13:00) - biospace.com/
LOGC | $2.07 -0.48%
|
Health Technology
|
| O: 65.68%
H: 5.81%
C: -20.56%
fda trial therapeutics clinical hold
Acer Therapeutics Announces Agreement with FDA on Special Protocol Assessment for its Phase 3 EDSIVO™ (celiprolol) Trial in Vascular Ehlers-Danlos Syndrome PatientsPhase 3 DiSCOVER clinical trial initiation expected by end of Q2 2022
Published: 2022-05-09 (Crawled : 13:00) - biospace.com/
ACER | $0.9 -3.61% 420K
|
Health Technology
|
| O: -2.83%
H: 0.97%
C: -9.22%
fda expected trial therapeutics phase 3
Eledon Pharmaceuticals Announces First Patient Dosed in Phase 2a Trial Evaluating Tegoprubart in IgA Nephropathy
Published: 2022-05-09 (Crawled : 13:00) - biospace.com/
ELDN | $1.57 -1.88% 3.03% 0
|
Manufacturing
|
| O: 0.71%
H: 0.18%
C: -12.63%
nephropathy trial phase 2b
Mereo BioPharma announces Positive Top-Line Efficacy and Safety Data from “ASTRAEUS” Phase 2 Trial of Alvelestat in Alpha-1 Antitrypsin Deficiency-associated Emphysema
Published: 2022-05-09 (Crawled : 12:00) - biospace.com/
MREO | $2.58 -4.09% -3.86% 1.6K
|
Health Technology
|
| O: 1.77%
H: 0.97%
C: -31.05%
biopharma trial positive topline phase 2 alvelestat
Gainers vs Losers
| 48% | 52% |
Top 10 Gainers
AGBA | $1.44 260.0% 40M
|
Finance
BPTH | $6.25 92.9% 20M
|
Health Technology
EGOX | $0.0447 39.25% 24M
|
BNTC | $5.91 23.13% 1.3M
|
Health Technology
XPON | $2.33 20.73% 410K
|
BRSH | $0.0515 15.99% 12M
|
n/a
VTNR S | $1.12 14.38% 470K
|
Industrial Services
DXYZ 4 | $33.49 13.41% 210K
|
n/a
BMI 4 | $169.84 11.01% 68K
|
Producer Manufacturing
CTM | $0.244 10.86% 40K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.